In Week of Mar 28, 2026, Dr Reddys Laboratories Ltd (Pharma - Formulators) is outperforming Nifty 500 with +12.6% relative strength. Fundamentals: Average. On a 5-week streak.
Weekly presence in the outperformers list. Green = beating Nifty 500 by 10%+ that week.
Based on Q3 FY26 earnings • Updated Feb 28, 2026
What: Near-term commercialization with $100+ million revenue potential over 2-3 years
Impact: +₹700 Cr revenue
“Management stated: 'How significant it is now? It's not that significant, but we should absolutely see, I believe, $100+ million coming to us as a growth in the next two to three years from that.'”
What: Entry into $4 billion market with immediate revenue generation
Impact: +₹1200 Cr revenue
“Management confirmed EU/UK approval while advancing 'key pipeline programs, Magnota and Abatacept'”
What: Underlying business growth excluding legacy products driving sustainable performance
“'The performance reported this quarter was largely attributable to the double-digit growth delivered by our underlying base businesses, excluding lenalidomide, aided by favorable forex.'”
Earnings deceleration risks from management commentary
Trigger: USFDA requires additional data
Impact: -250 bps margin impact
Management view: Acknowledged CRL but no specific resolution timeline provided
Monitor: USFDA resubmission date
Trigger: Competitive pressure in North America generics
Impact: -120 bps margin impact
Management view: 'North America Generics revenue decreased by 16% YoY, primarily due to lower Lenalidomide sales'
Monitor: New product launch velocity
Key quotes from recent conference calls
“The business delivered a resilient performance in Q3 FY26, reporting a 4.4% revenue growth and steady profitability despite product-specific headwinds. — Erez Israeli”
“EBITDA margin stood at 23.5%, which included a one-time provision related to the new labor codes mentioned earlier. Excluding this one-time provision, EBITDA margin is at 24.8%, like I mentioned, about 25%. — Erez Israeli”
“Our emerging market business delivered revenue of ₹1,896 crores in Q3 FY26, reflecting a robust growth of 32% year on year and 15% sequentially. — Erez Israeli”
“Annualized ROC was at 20.4%. — Erez Israeli”
Forward-looking targets from management for next_2-4_quarters
Implied PAT Growth
10%
OPM Guidance
25%
Capex Plan
₹1050 Cr
Key Milestones
• Semaglutide launch
• Denosumab EU commercialization
• USFDA resubmission for denosumab
Revenue, profit and margin growth rates
| Metric | YoY | 3Y CAGR | Trend |
|---|---|---|---|
| Revenue | +4% | +15% | Decelerating |
| PAT (Net Profit) | -15% | +38% | Inflection Down |
| OPM | 22.0% | -500 bps | Volatile |
The above analysis is parsed from publicly available earnings call transcripts. This is educational research only — not investment advice. Last updated Feb 28, 2026.
Based on publicly available financial data. This is educational research, not investment advice.
Dr Reddys Laboratories Ltd's latest quarterly results (Dec 2025) show
Dr Reddys Laboratories Ltd's profit is declining with an inflecting downward trend.
Dr Reddys Laboratories Ltd's revenue growth trend is decelerating.
Dr Reddys Laboratories Ltd's operating margin is volatile.
Dr Reddys Laboratories Ltd's long-term compounding rates
Dr Reddys Laboratories Ltd's earnings growth is inflecting downward with negative momentum on a sequential basis.
Dr Reddys Laboratories Ltd's trailing twelve month (TTM) performance
Dr Reddys Laboratories Ltd appears significantly undervalued based on our fair value analysis.
Dr Reddys Laboratories Ltd's current PE ratio is 19.2x.
Dr Reddys Laboratories Ltd's current PE is 19.2x.
Dr Reddys Laboratories Ltd's price-to-book ratio is 3.0x.
Dr Reddys Laboratories Ltd is rated Average with a fundamental score of 42.53/100. This score is calculated from objective financial metrics
Dr Reddys Laboratories Ltd has a debt-to-equity ratio of N/A.
Dr Reddys Laboratories Ltd's return ratios over recent years
Dr Reddys Laboratories Ltd's operating cash flow is positive (FY2025).
Dr Reddys Laboratories Ltd's current dividend yield is 0.62%.
Dr Reddys Laboratories Ltd's shareholding pattern (Dec 2025)
Dr Reddys Laboratories Ltd's promoter holding has remained stable recently.
Dr Reddys Laboratories Ltd has been outperforming Nifty 500 for 5 consecutive weeks, indicating building momentum.
Dr Reddys Laboratories Ltd is an established outperformer with 5 weeks of consecutive Nifty 500 outperformance.
Dr Reddys Laboratories Ltd has 3 key growth catalysts identified from recent earnings analysis
Dr Reddys Laboratories Ltd has 2 key risks worth monitoring
In Q3 FY26, Dr Reddys Laboratories Ltd's management highlighted
Dr Reddys Laboratories Ltd's management has provided the following forward guidance for next_2-4_quarters
Based on quantitative research signals, here is why Dr Reddys Laboratories Ltd may be worth studying
Dr Reddys Laboratories Ltd investment thesis summary:
Dr Reddys Laboratories Ltd's forward outlook based on current data signals
The above FAQs are generated from publicly available earnings data and conference call transcripts. This is educational research only. Sector Alpha is not SEBI registered and does not provide investment advice.
